中国现代医学杂志2025，Vol.35Issue(15)：38-42,5.DOI:10.3969/j.issn.1005-8982.2025.15.006
沙格列汀联合苯溴马隆对糖尿病患者合并高尿酸血症的疗效分析
Efficacy analysis of saxagliptin combined with benzbromarone in diabetic patients with hyperuricemia
摘要
Abstract
Objective To investigate the clinical efficacy of saxagliptin combined with benzbromarone in diabetic patients with hyperuricemia.Methods A prospective study was conducted on 82 diabetic patients with hyperuricemia admitted to our hospital between February 2018 and October 2022.Patients were randomly divided into a control group(n=41,saxagliptin alone)and an observation group(n=41,saxagliptin+benzbromarone).Both groups were treated for 12 weeks.Changes in blood glucose[fasting blood glucose(FBG),2-hour postprandial blood g1ucose(2 hPG),hemoglobin A1c(HbA1c)],fasting insulin(FINS),uric acid(UA),serum creatinine(Scr),blood urea nitrogen(BUN),and blood lipids[total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C)]were compared,along with clinical efficacy and adverse reactions.Results The magnitude of change(pre-vs.post-treatment)in FBG,2hPG,HbA1c,FINS,UA,Scr,and BUN was significantly greater in the observation group than in the control group(P<0.05).The magnitude of change in TC,TG,and LDL-C was also significantly greater in the observation group(P<0.05).The total clinical efficacy rate was significantly higher in the observation group than in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Saxagliptin combined with benzbromarone effectively reduces blood glucose,insulin,UA,Scr,BUN,and lipid levels in diabetic patients with hyperuricemia,improving clinical efficacy with a favorable safety profile.关键词
糖尿病/高尿酸血症/沙格列汀/苯溴马隆/临床疗效Key words
diabetes/hyperuricemia/saxagliptin/benzbromarone/clinical efficacy分类
医药卫生引用本文复制引用
陈晨,张玉皎..沙格列汀联合苯溴马隆对糖尿病患者合并高尿酸血症的疗效分析[J].中国现代医学杂志,2025,35(15):38-42,5.基金项目
江苏省卫生健康委科研重点项目(No:ZD2022037) （No:ZD2022037）
